Post de adMare BioInnovations

Good results in this round of funding for a uniquely differentiated and disruptive project.

Indeed, it was an interesting discussion about the #ATMP translation into commercialization and accessibility challenges. The comparability and robustness issues & with quality and safety in mind were mentioned as well. It is not always easy to have all the required expertise in house. Therefore the collaborative approach could be a good solution for the #ATMP developers.

ARG-007 has reached a number of key clinical milestones, with Argenica currently preparing for Stage 2 clinical trials later this year. Here are just a few things that sets ARG-007 apart when it comes to stroke therapeutics. To learn more, download our most recent Investor Presentation: https://bit.ly/3EpPzPO #ASX #AGN #ARG007 #stroketheraputics #clinicaltrials

Do you want an update on what's been happening at Argenica Therapeutics? This morning, we released our most recent Investor Presentation, providing an update on our Phase 2 Clinical Trial. Read the full presentation here➡️ https://bit.ly/4f4NZ70 #clinicaltrial #investorupdate #AGN #ASX #stroke #strokeawareness

AsclepiX Therapeutics, Inc. has announced that it has secured a $10 million Series A-3 financing. The round was led by Perceptive Advisors with participation from the existing investors Hibiscus Capital Management Fund II and Rapha Capital Management, LLC and its managed fund, Rapha Capital Management, LLC PE Life Sciences Fund VI, in addition to a new outside investor. The lead clinical candidate, integrin regulating peptide AXT107 (gersizangitide), has a novel mechanism of action that inhibits neovascularization, reduces vascular permeability, and suppresses vascular inflammation. In a microparticulate suspension, AXT107 may be capable of maintaining sustained biological activity with one injection well beyond current standard of care. https://bit.ly/3rH7VZw

Fascinating keynote panel by Miguel Forte from Kiji Therapeutics, Tara Sadeghi from Cellenkos, Inc. Seth Ettenberg from BlueRock Therapeutics and Katy Newton from Achilles Therapeutics plc talking about key considerations for ensuring commercial sustainability! #adtherapies24

Check this out! As a scientist, patent attorney and entrepreneur, I believe that innovation is the genesis of therapeutics that changes patients lives. Get informed and support strong patent rights to protect these innovations and the businesses that they help build!

4/17 Webinar: How to take back control of your #ITHelpdesk from #Slack DMs. Cohere, Xilio Therapeutics, Foqal share experience. Register here: https://hubs.ly/Q02pyRpN0